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The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later came to be known as amyloid plaques and neurofi brillary tangles (Figure 1 ). The case report was published in a psychiatric textbook some years later, and this peculiar and (at the time) seemingly rare illness was later named Alzheimer's disease.
Humans differ from other primates through their superior intellectual and mental abilities. When a gradual and chronic loss of these cognitive functions leads to a loss of independent living, the individual is described as being demented. Such declining cognitive functions encompass all mental processes involved in acquiring knowledge and practical skills, including memory, language, reasoning and attention. Today, Alzheimer's disease is the most prevalent neurodegenerative disorder, comprising approximately 60% of dementia cases. With steadily improving standards of living, people in developed regions of the world are living longer, and Alzheimer's disease is associated strongly with old age. The number of cases of Alzheimer's disease has been increasing steadily, and with today's aging population, the number of people with dementia worldwide is expected to quadruple by 2050 unless effective treatment or prevention becomes available. In this Primer, we consider the symptoms, biological basis and potential biomarkers of Alzheimer's disease.
Symptoms and risk factors
Separating changes associated with normal aging from the early symptoms Primer of Alzheimer's disease is challenging because of the disease's gradual development and the subtlety of the initial changes in cognitive function. The fi rst symptom is often a change in episodic memory, more specifi cally the amnestic syndrome, where free and cued recall abilities are impaired. Remembering new information becomes diffi cult, and as the disease progresses, executive dysfunction and problems in language and spatial orientation occur. Activities of daily living such as dressing and eating are usually not impaired until the disease progresses further. There are large variations in the course of the disease when it comes to types of symptom and rate of progression. Because there is no cure, most patients eventually reach the dementia phase of Alzheimer's disease, though as the disease usually starts in later life and can progress over many years, some patients may die prior to dementia.
Who will develop Alzheimer's disease, and is it possible to prevent it? The cause of Alzheimer's disease is probably multifactorial, consisting of a cocktail of environmental, lifestyle and genetic factors. Risk factors for Alzheimer's disease are classifi ed as modifi able or non-modifi able, the latter being age and individual genetic profi les. There have been numerous studies attempting to identify modifi able risk factors. Those that have been reliably documented include cardiovascular risk factors such as hypertension, diabetes, obesity, physical inactivity and smoking. Other modifi able risk factors of importance are cognitive inactivity and a low level of education, perhaps due to what has been termed 'cognitive reserve', whereby individuals with higher education and mental stimulation are believed to have developed more synapses, allowing them to withstand neurodegeneration for a longer period of time.
Modifi able risk factors have been estimated to represent 35% of the total risk of Alzheimer's disease, suggesting that increased focus on them could lead to prevention of up to one-third of all cases. Postponing symptom onset by only one year could potentially lower Alzheimer's disease prevalence by 11%, equivalent to more than 9 million cases worldwide New diagnostic criteria that enable identifi cation of people in the preclinical phase of Alzheimer's disease will be the key for early intervention, treatment and prognosis. As of today, we cannot cure affected neurons, and it is crucial that intervention is made before neuronal loss begins.
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The amyloid hypothesis
A healthy brain contains about 86 billion neurons. One neuron may connect with up to 10,000 other neurons, passing signals via 1000 trillion synaptic connections. Alzheimer's disease leads to a gradual and irreversible loss of many of these neurons and synapses. The typical histopathological alterations thought to be the hallmark of the disease are the plaques and neurofi brillary tangles originally seen and drawn by Alzheimer. These are caused by an accumulation of amyloidbeta peptide in brain tissue, and hyperphosphorylation of microtubuleassociated tau protein in neurons.
Amyloid beta peptides are composed of a various number of amino acids, and generated through proteolytic cleavage of amyloid precursor protein (APP) by several enzyme complexes known as secretases. Cleavage by -secretase and subsequently by the -secretase complex forms non-amyloidogenic products of APP. An alternative amyloidogenic pathway, with cleavage of APP fi rst by the -secretase BACE1, and subsequently by the -secretase complex, leads to an accumulation of insoluble amyloid beta proteins in the brain.
The accumulation of amyloid beta is thought to trigger a neurotoxic cascade, leading to plaque formation, phosphorylation of tau protein, formation of neurofi brillary tangles, infl ammation, synaptic loss and eventually neuronal death. The pathology usually starts in the brain regions involved in learning and memory, more specifi cally the hippocampus and entorhinal cortex in the temporal lobe, eventually spreading to the entire cortex.
There has been a substantial amount of skepticism towards the amyloid hypothesis ever since its fi rst description in the 1980s. Critics often claim APP has neurotropic effects, sharing similar structural features with the precursor of epidermal growth factor, suggesting that increased expression of APP and subsequent increases in amyloid deposition are a response to neuronal injury rather than a pathological driver of the disease. The large amount of failed therapeutic trials targeting amyloid deposition is often used as confi rmation of this theory. However, the strong correlation between mutations in the Current Biology 28, R635-R655, June 4, 2018 R647 PSEN1, PSEN2 and APP genes and trisomy 21, which all lead to increased accumulation of amyloid plaques and the development of early-onset familial Alzheimer's disease, strongly supports the amyloid hypothesis. PSEN1 and PSEN2 are important components of the -secretase complexes responsible for the cleavage and release of A. The APP gene is located in chromosome 21 and mutations in the gene itself or trisomy 21 result in increased levels of amyloid beta. Also A42 peptides isolated from late-onset Alzheimer's disease human brains cause memory defi cits, long-term synaptic depression and decreased synapse density when injected to rodent brains, thereby providing further support for the amyloid hypothesis.
Genetics
The gene for apolipoprotein E (APOE) was the fi rst identifi ed susceptibility gene for late-onset Alzheimer's disease, which is by far the most common form. ApoE is a protein mainly involved in cholesterol metabolism and transport, and it transports cholesterol to neurons via ApoE receptors. The APOE gene comes in three main isoforms; 2, 3 and 4, which have a worldwide frequency of 1-5%, 50-90%, and 5-35%, respectively. The isoforms have different impacts on accumulation and clearance of amyloid beta in the brain, and the reduced ability of the ApoE4 isoform of the protein to remove deposited amyloid may be the reason that APOE4 is the most important genetic risk factor for lateonset Alzheimer's disease. Having one copy of APOE4 increases the risk for late-onset Alzheimer's disease threefold, while individuals with two copies have an eight-to twelve-fold increased risk of developing the disease.
Recent studies also show that the overall heritable risk of sporadic lateonset Alzheimer's disease is complex, with a large polygenic contribution. In addition to the ApoE polymorphism, genome-wide association studies have identifi ed several other genetic loci to be associated with the disease, suggesting that there are many other susceptibility genes contributing to its intricate biological pathway. Polygenic risk scores have been developed based on these loci, enabling calculation of an individual genetic risk profi le. In the future, polygenic risk scores could be valuable in selecting young individuals at risk for Alzheimer's disease, allowing for early intervention with respect to modifi able risk scores.
Biomarkers
An ideal biomarker for Alzheimer's disease should have high specifi city and sensitivity, clearly separating the disease from other types of dementia as well as from healthy individuals. Biomarkers used for the detection of Alzheimer's disease can be divided into two main groups; measurements of specifi c proteins in cerebrospinal fl uid (CSF), and neuroimaging techniques. Validated biomarkers in CSF include reduction in the level of -amyloid (A42), increased total tau and phosphorylated tau-181. A combination of these three biomarkers increases the diagnostic validity for sporadic Alzheimer's disease compared to healthy controls with a combined sensitivity of >95% and specifi city of >85%.
Magnetic resonance imaging (MRI) and positron emission tomography (PET) can be used to measure amyloid and tau deposition, brain metabolism and brain volume. Amyloid PET uses a labeled amyloid tracer, and the cortico/ cerebellar standardized uptake value/ ratio is calculated as an index for A-deposits. Certain regions of interest in the brain are determined, and the uptake is compared to a cerebellar reference. This allows objective measurement, with higher sensitivity and specifi city than visual inspections of scans. Studies have confi rmed its ability to separate Alzheimer's disease patients from control subjects, and A42 in CSF and amyloid plaque deposition in brain are inversely correlated. Low -amyloid (1-42) and high total tau and phosphorylated tau-181 in CSF and/or high retention of amyloid tracer measured with amyloid PET in connection with Alzheimer's disease are required as pathophysiological markers according to the latest research criteria.
A decline in A42 in CSF can be detected up to 20 years before onset of symptoms, whereas amyloid PET can detect pathological deposition of amyloid plaques up to 15-20 years before the fi rst symptom occurs. Considering the high costs of Alzheimer's disease dementia, it has been suggested that in the future, middle-aged people should be screened through sampling of CSF, selecting those with low A42 for further investigation with PET. If pathological amyloid deposition is confi rmed, these individuals could be selected for early, presymptomatic therapeutic interventions when available.
But although CSF sampling is relatively inexpensive, it is an invasive procedure, and therefore has a certain risk of complications. On the other hand, amyloid PET is a highly expensive 
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imaging technique, exposes the patient to (short-term) radiation, and has limited availability even in wealthy countries. There has been a considerable amount of research on various bloodbased biomarkers in Alzheimer's disease, identifying the intricacy of the pathobiology of the disease, but none yet fulfi l the diagnostic accuracy of amyloid PET/CSF core biomarkers. A recently published paper has shown promising results for a blood-based (plasma) amyloid -biomarker using immunoprecipitation coupled with mass spectrometry. The ideal screening method, however, would be a bloodbased biomarker that separates Alzheimer's disease from other dementias, and also monitors disease progression and effect of therapy. No such biomarker exists today. There are also several ethical issues to screening. Should the clinician communicate to cognitively normal middle-aged individuals that they are in a preclinical stage of Alzheimer's disease, and if so how?
A potential new biomarker for early detection of Alzheimer's disease Through decades of research, the hippocampal formation has been demonstrated to contribute substantially to memory formation and retrieval, as well as to navigation and the representation of space. Studies in freely moving rodents have revealed place-modulated neuronal activity in two key structures of the hippocampal formation; place cells in the hippocampus and grid cells in the entorhinal cortex. Reports of similar neuronal substrates in monkeys, bats and humans showed that neuronal coding in these areas is highly conserved across species, and suggests an importance for many fundamental processes in the brain.
While hippocampal place cells fi re whenever an animal enters a certain place in its environment (the neuron's place fi eld), entorhinal grid cells fi re periodically at multiple locations and form a six-fold rotationally symmetrical grid-like fi ring pattern across space (the neuron's grid fi eld). The neuronal population code emerging from these two spatially tuned cell types is assumed to provide an internal, cognitive map. Importantly, recent evidence suggests that the functional role of grid cells and place cells extends well beyond navigation through space. For example, if rats have to recognize a certain pitch of frequency in a tone, grid cells show representation of discrete 'frequency locations' on the continuous dimension of pitch.
The grid-cell system also seems to map visual space even without actual navigation. In both monkeys and humans, studies found the sixfold rotationally symmetrical grid-celllike activity typical of grid cells that depended on where subjects were looking on a computer screen. Lastly, the grid cell system has been implicated in the organization of abstract conceptual spaces in humans.
Human grid-cell representations can be investigated with functional magnetic resonance imaging (fMRI), where changes in blood oxygenation levels correlate with neuronal activity. When analyzing blood oxygenation level dependent (BOLD) responses as a function of the participant's movement direction in virtual reality, a six-fold rotational dependency of entorhinal activity (hexadirectional signal) was found that correlated with how well participants remembered locations. This fMRI-based method provides a promising, non-invasive window into the population activity of grid-like coding in humans.
Importantly, the entorhinal cortex is among the fi rst regions affected by Alzheimer's disease-related pathology. Entorhinal grid cell-like representations are already altered in young adults at genetic risk for Alzheimer's disease (APOEe4 heterozygotes), decades before potential onset of cognitive decline or general defi cits in spatial memory. APOEe4 carriers also showed subtle changes in navigational strategy, such as moving close to the boundary in a virtual arena environment. These behavioral differences, as well as increased activity in parts of the hippocampus, could refl ect compensatory mechanisms for impaired entorhinal processing. Compromised grid-cell-like representations have subsequently been associated with agerelated navigational defi cits and studies in matured mice at genetic risk for Alzheimer's disease-related pathology showed impairments in both grid cell activity and spatial memory (Figure 3) .
In summary, the entorhinal cortex and hippocampus play central roles in spatial navigation and memory and form a system that organizes memory-guided behaviors. Unsurprisingly, the degradation of this system in Alzheimer's disease is associated with severe impairments Kunz et al. (2015) One explanation for this may be that the intervention came too late in the disease continuum, often in the early dementia phase, when brain pathology has evolved too far and the neuronal damage is too large. Patient selection has also often been based on a clinical diagnosis alone, so it has been unclear whether the participants have amyloid pathology or not. Optimizing selection of participants and better understanding the pathophysiological processes of Alzheimer's disease are essential to develop novel diseasemodifying drugs.
Future considerations
Alzheimer's disease research is still at an early stage compared to many other medical research fi elds. The establishment and understanding of the nonlinear dynamic Alzheimer's disease continuum has led to an important paradigm shift in the fi eld, but many aspects remain to be clarifi ed. Further studies on the complex biological pathways are essential.
The entorhinal cortex and hippocampus are usually the fi rst regions affected by Alzheimer's disease pathology. They play a key role in spatial navigation and memory, and form a system that appears to organize memory-guided behaviors based on continuous sensory or conceptual dimensions. The degradation of this system in Alzheimer's disease is therefore associated with severe impairments in memory and navigation. fMRI-based estimates of grid celllike-representations in the entorhinal cortex hold promise as a potential early prognostic marker for the development of cognitive and memory impairment in Alzheimer's disease.
Existing Alzheimer's disease biomarkers support accurate and early diagnosis, and also aid selection of suitable individuals for intervention, thus increasing optimism for upcoming therapeutic trials. Nevertheless, the existing biomarkers have limited relevance and multiple biomarkers will need to be developed; for understanding pathophysiological changes associated with the Alzheimer's disease continuum, identifying asymptomatic individuals at risk of disease with high sensitivity and specifi city, distinguishing Alzheimer's disease from other forms of dementia, measuring the effect of therapy, and excluding individuals at risk of developing dangerous side effects of specifi c treatments. So the hunt for new biomarkers will continue. In this regard, the development of blood-based biomarkers would be advantageous as blood sampling is not considered particularly invasive, samples are quickly and easily obtained, the risk is minimal, and in a medico-social context they would be by far the most costeffective.
Although effective therapy to stop or delay Alzheimer's disease progression has long been, and remains, a major goal, this does not have to be drugbased. One crucial aspect that has only recently received marked attention regards the clear possibilities for disease prevention, or at least delay of disease onset, that can often be achieved through simple changes in lifestyle. Campaigns through the media regarding modifi able risk factors could be easily arranged, and would have the added advantage of benefi cial effects on other major aspects of public health, like obesity, vascular disease and diabetes. It would also be extremely cost-effective compared to the development of drug-based therapies. Indeed, intervention studies focusing on vascular risk factors, physical activity and cognitive training have shown promising results in delaying cognitive decline, and as of today are a better therapy against Alzheimer's disease than any current drug-based treatment.
